Mycosis fungoides diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
== Diagnostic Study of Choice == | == Diagnostic Study of Choice == | ||
Mycosi fungoides must be performed when:<ref name="pmid20568590">{{cite journal |vauthors=Galper SL, Smith BD, Wilson LD |title=Diagnosis and management of mycosis fungoides |journal=Oncology (Williston Park, N.Y.) |volume=24 |issue=6 |pages=491–501 |date=May 2010 |pmid=20568590 |doi= |url=}}</ref> | *Mycosi fungoides must be performed when:<ref name="pmid20568590">{{cite journal |vauthors=Galper SL, Smith BD, Wilson LD |title=Diagnosis and management of mycosis fungoides |journal=Oncology (Williston Park, N.Y.) |volume=24 |issue=6 |pages=491–501 |date=May 2010 |pmid=20568590 |doi= |url=}}</ref> | ||
* The patient presents with symptomatic progressive skin lesions such as: patches, plaques, tumors, and erytheroderma, and a poorer prognosis in later stages. | **The patient presents with symptomatic progressive skin lesions such as: patches, plaques, tumors, and erytheroderma, and a poorer prognosis in later stages. | ||
* There is no single diagnostic study of choice for the diagnosis of mycosis fungoides, and mycosis fungoides can be diagnosed difficult by nonspecific skin presentation. | **There is no single diagnostic study of choice for the diagnosis of mycosis fungoides, and mycosis fungoides can be diagnosed difficult by nonspecific skin presentation. | ||
* Lesions disease present with skin lesions not treated by useual medication. | **Lesions disease present with skin lesions not treated by useual medication. | ||
* Mycosis fungoides is primarily diagnosed based on the clinical presentation. | **Mycosis fungoides is primarily diagnosed based on the clinical presentation. | ||
Diagnosis criteria from the International Society for Cutaneous Lymphoma is:<ref name="FossGirardi2017" /><ref name="PimpinelliOlsen2005">{{cite journal|last1=Pimpinelli|first1=Nicola|last2=Olsen|first2=Elise A.|last3=Santucci|first3=Marco|last4=Vonderheid|first4=Eric|last5=Haeffner|first5=Andreas C.|last6=Stevens|first6=Seth|last7=Burg|first7=Guenter|last8=Cerroni|first8=Lorenzo|last9=Dreno|first9=Brigitte|last10=Glusac|first10=Earl|last11=Guitart|first11=Joan|last12=Heald|first12=Peter W.|last13=Kempf|first13=Werner|last14=Knobler|first14=Robert|last15=Lessin|first15=Stuart|last16=Sander|first16=Christian|last17=Smoller|first17=Bruce S.|last18=Telang|first18=Gladys|last19=Whittaker|first19=Sean|last20=Iwatsuki|first20=Keiji|last21=Obitz|first21=Erik|last22=Takigawa|first22=Masahiro|last23=Turner|first23=Maria L.|last24=Wood|first24=Gary S.|title=Defining early mycosis fungoides|journal=Journal of the American Academy of Dermatology|volume=53|issue=6|year=2005|pages=1053–1063|issn=01909622|doi=10.1016/j.jaad.2005.08.057}}</ref> | *Diagnosis criteria from the International Society for Cutaneous Lymphoma is:<ref name="FossGirardi2017" /><ref name="PimpinelliOlsen2005">{{cite journal|last1=Pimpinelli|first1=Nicola|last2=Olsen|first2=Elise A.|last3=Santucci|first3=Marco|last4=Vonderheid|first4=Eric|last5=Haeffner|first5=Andreas C.|last6=Stevens|first6=Seth|last7=Burg|first7=Guenter|last8=Cerroni|first8=Lorenzo|last9=Dreno|first9=Brigitte|last10=Glusac|first10=Earl|last11=Guitart|first11=Joan|last12=Heald|first12=Peter W.|last13=Kempf|first13=Werner|last14=Knobler|first14=Robert|last15=Lessin|first15=Stuart|last16=Sander|first16=Christian|last17=Smoller|first17=Bruce S.|last18=Telang|first18=Gladys|last19=Whittaker|first19=Sean|last20=Iwatsuki|first20=Keiji|last21=Obitz|first21=Erik|last22=Takigawa|first22=Masahiro|last23=Turner|first23=Maria L.|last24=Wood|first24=Gary S.|title=Defining early mycosis fungoides|journal=Journal of the American Academy of Dermatology|volume=53|issue=6|year=2005|pages=1053–1063|issn=01909622|doi=10.1016/j.jaad.2005.08.057}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
Revision as of 16:10, 12 February 2019
|
Mycosis fungoides Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mycosis fungoides diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Mycosis fungoides diagnostic study of choice |
|
Risk calculators and risk factors for Mycosis fungoides diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Mycosis fungoides is primarily diagnosed based on the clinical presentation.
Diagnostic Study of Choice
- Mycosi fungoides must be performed when:[1]
- The patient presents with symptomatic progressive skin lesions such as: patches, plaques, tumors, and erytheroderma, and a poorer prognosis in later stages.
- There is no single diagnostic study of choice for the diagnosis of mycosis fungoides, and mycosis fungoides can be diagnosed difficult by nonspecific skin presentation.
- Lesions disease present with skin lesions not treated by useual medication.
- Mycosis fungoides is primarily diagnosed based on the clinical presentation.
| Criteria | Major( 2pinots) | Minor(1point) |
|---|---|---|
| Persistent and/or progressive patches and plaques plus | Any 2 | Any 1 |
| Clinical | ||
| 1. Non–sun-exposed location | ||
| 2.Size/shape variation | ||
| 3.Poikiloderma | ||
| Histopathologic | ||
| Superficial lymphoid infiltrate plus | Both | Either |
| 1. Epidermotropism | ||
| 2. Atypia | ||
| Molecular/biological | ||
| Clonal TCR gene rearrangement | Present | |
| Immunopathologic | ||
| 1. CD2, CD3, CD5 in <59% of T cells | Any 1 | |
| 2. CD7 in <10% of T cells | ||
| 3. Epidermal discordance from expression of CD2, CD3, CD5, and CD7 on dermal T cells | ||
Diagnosis criteria from the International Society for Cutaneous Lymphoma is:[2][3]
| Criteria | Major( 2pinots) | Minor(1point) |
|---|---|---|
| Persistent and/or progressive patches and plaques plus | Any 2 | Any 1 |
| 1. Non–sun-exposed location | ||
| 2.Size/shape variation | ||
| 3.Poikiloderma | ||
| Histopathologic | ||
| Superficial lymphoid infiltrate plus | Both | Either |
| 1. Epidermotropism | ||
| Molecular/biological | ||
| 2. Atypia | ||
| Clonal TCR gene rearrangement | Present | |
| Immunopathologic | ||
| 1. CD2, CD3, CD5 in <59% of T cells | Any 1 | |
| 2. CD7 in <10% of T cells | ||
| 3. Epidermal discordance from expression of CD2, CD3, CD5, and CD7 on dermal T cells | ||
OR
IF there are clear, established diagnostic criteria
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
IF there are no established diagnostic criteria
There are no established criteria for the diagnosis of [disease name].
Staging
References
- ↑ Galper SL, Smith BD, Wilson LD (May 2010). "Diagnosis and management of mycosis fungoides". Oncology (Williston Park, N.Y.). 24 (6): 491–501. PMID 20568590.
- ↑ 2.0 2.1
- ↑ 3.0 3.1 Pimpinelli, Nicola; Olsen, Elise A.; Santucci, Marco; Vonderheid, Eric; Haeffner, Andreas C.; Stevens, Seth; Burg, Guenter; Cerroni, Lorenzo; Dreno, Brigitte; Glusac, Earl; Guitart, Joan; Heald, Peter W.; Kempf, Werner; Knobler, Robert; Lessin, Stuart; Sander, Christian; Smoller, Bruce S.; Telang, Gladys; Whittaker, Sean; Iwatsuki, Keiji; Obitz, Erik; Takigawa, Masahiro; Turner, Maria L.; Wood, Gary S. (2005). "Defining early mycosis fungoides". Journal of the American Academy of Dermatology. 53 (6): 1053–1063. doi:10.1016/j.jaad.2005.08.057. ISSN 0190-9622.